Mid Atlantic Bio Angels (MABA) announces today that the New York Genome Center (NYGC) will be the host sponsor of all 2015 1st Pitch Life Science events at the NYGC’s facilities at 101 Avenue of the Americas in New York City.
At a 1st Pitch Life Science event, early stage life sciences companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company’s presentation, business model and perceived viability in the market.
“The 1st Pitch events have shown their value, both in giving emerging companies an opportunity to refine the way they discuss their offering and strategies and offering the audience insights into the do’s and don’ts of pitching a science-based company,” said Yaniv Sneor, MABA Co-Founder and President of Blue Cactus Consulting. “We’re excited that the New York Genome Center perceives the synergies with its own initiatives, which also support emerging companies through its consortium of academics and scientists who are working to improve clinical care through genomic research.”
“Working together with MABA, we believe that there is tremendous opportunity for emerging biotech companies to learn from one another and from the vast resources available to both organizations,” said Sara Ghazaii, Director of Communications, New York Genome Center. “We look forward to hosting a variety of interesting and cutting-edge companies presenting to an audience of engaged life science industry participants, and to facilitating the interactions among all of the attendees.”
About MABA
Mid Atlantic Bio Angels is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA’s goal is to create an environment where the depth of investors’ knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.
About New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations and partners are united in this unprecedented collaboration of technology, science, and medicine. We harness the power of innovation and discoveries to improve people’s lives – ethically, equitably, and urgently. Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University College of Physicians and Surgeons, Cornell University/Weill Cornell Medical College, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan-Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, NewYork-Presbyterian Hospital, The New York Stem Cell Foundation, New York University, North Shore-LIJ, The Rockefeller University, Roswell Park Cancer Institute, Stony Brook University and IBM. For more information, visit: nygenome.org.
